Work

A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma

Year: 2020

Type: article

Study design: Clinical Trial

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2020.06.009

Authors: J.F. Liu, N. Tayob, S.M. Campos, A.A. Wright, C. Krasner, S. Schumer, N.S. Horowitz, J.L.T. Veneris, N. Xiong, G. West, R. Quinn, U.A. Matulonis, P.A. Konstantinopoulos

Institutions: Dana-Farber Cancer Institute, Brigham and Women's Hospital, Dana-Farber Brigham Cancer Center

Language: English

Topic: Endometrial and Cervical Cancer Treatments

Subfield: Obstetrics and Gynecology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3014869341

FWCI: 0.595

Cites:

Cited by: 7

Related to: 10